FindTrial
Sign In

The effect of intrathecal dexmedetomidine for the median effective dose (ED50) of intrathecal hyperbaric ropivacaine in caesarean section

The effect of intrathecal dexmedetomidine for the median effective dose (ED50) of intrathecal hyperbaric ropivacaine in caesarean section

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018551
Enrollment
Unknown
Registered
2018-09-23
Start date
2018-10-01
Completion date
Unknown
Last updated
2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain

Interventions

Group 2:ropivacaine
Group 1:dexmedetomidine+ropivacaine

Sponsors

Women's Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Elective cesarean section in healthy parturient

Exclusion criteria

Exclusion criteria: Patients with respiratory, cardiovascular, renal, hepatic, endocrine and neurological diseases were excluded.

Design outcomes

Primary

MeasureTime frame
age, height, weight, Gestational week, pregnancy;operation time;Neonatal weight;apger;side effects;Phenylephrine;characteristic of the sense/motor block;nausea and vomit, shivering, pruritus, bradycardia, hypotention;umbilical artery blood gas analysis;—

Countries

China

Contacts

Public ContactMeijuan Yang

Women's Hospital, School of Medicine, Zhejiang University

yangmeijuan2008@163.com+86 15088688422

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026